secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-08-06T21:15:10+00:00
Accession:  0001104659-26-092128
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor
--------------------------------------------------------------------------------

- Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.
- Commission of 3.0% of gross proceeds payable to agents; no minimum offering amount required.
- Replaces prior $100M ATM agreement dated February 27, 2025; new agreement has no stated maximum.
- Shares sold under existing Form S-3 registration statement; Company retains discretion on timing and size.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/0001104659-26-092128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/acrs-20260806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer